Navigation Links
FDA Approves Vaccines for 2009 H1N1 Influenza Virus
Date:9/15/2009

Approval Provides Important Tool to Fight Pandemic

WASHINGTON, Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

"Today's approval is good news for our nation's response to the 2009 H1N1 influenza virus," said Commissioner of Food and Drugs Margaret A. Hamburg, M.D. "This vaccine will help protect individuals from serious illness and death from influenza."

The vaccines are made by CSL Limited, MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and sanofi pasteur Inc. All four firms manufacture the H1N1 vaccines using the same processes, which have a long record of producing safe seasonal influenza vaccines.

"The H1N1 vaccines approved today undergo the same rigorous FDA manufacturing oversight, product quality testing and lot release procedures that apply to seasonal influenza vaccines," said Jesse Goodman, M.D., FDA acting chief scientist.

Based on preliminary data from adults participating in multiple clinical studies, the 2009 H1N1 vaccines induce a robust immune response in most healthy adults eight to 10 days after a single dose, as occurs with the seasonal influenza vaccine.

Clinical studies under way will provide additional information about the optimal dose in children. The recommendations for dosing will be updated if indicated by findings from those studies. The findings are expected in the near future.

As with the seasonal influenza vaccines
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
... an,entrepreneur trained in Pilates, is bringing the latest Pilates ... Element Pilates.,Ilitch,s version of the innovative barre workout is ... and dance exercises,in rapid sequence to tone and transform ... any other studios in the area. According to ...
... on Cold and ... ... a division of,American Scientific Resources (Pink Sheets: ASFX), today announced the,launch ... world, now available at Walgreens Stores,nationwide and online at http://www.kidzmed.com ...
... health care system is one of only five organizations ... DIEGO, Nov. 20 President,George W. Bush and Commerce ... five organizations to receive the 2007 Malcolm,Baldrige National Quality ... performance excellence. (Photo: http://www.newscom.com/cgi-bin/prnh/20071120/DC07985-a ...
... Jewelers returns to national campaign for fourth year to support ... in communities everywhere., AKRON, Ohio, Nov. 20 Kay ... off its annual Thanks and Giving,campaign. This is the fourth ... has partnered with St. Jude in fundraising campaigns. Thanks ...
... Eularis WHAT: Presentation on Marketing Return: What can be ... WHEN: 26 November 2007 at 2:30 p.m. GMT, WHERE: Pharmaceutical ... ... and LONDON, Nov. 20 Dr. Andree Bates,president of the pharmaceutical analytics company ...
Cached Medicine News:Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 3Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 2Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 3Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 2Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 3Health News:MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP? 2
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... 2014 In response to urgent requests from the Deputy ... Sierra Leone , Direct Relief delivered two 10-bed medical ... treatment of local health workers who contract Ebola while fighting ... care center was constructed for foreign health care workers who ... for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Switzerland, Jan. 9 ESBATech AG, a leading developer ... of the Phase I/IIa clinical development of its ... This double-blind, randomized, placebo-controlled Phase I/IIa clinical study ... efficacy on pain with ESBA105 applied locally via ...
... transplantation to be Quark,s second indication with ... Calif., Jan. 8 Quark Pharmaceuticals, Inc., ... novel RNA interference (RNAi)-based therapeutics, today announced ... its Phase I/II clinical trial evaluating its ...
Cached Medicine Technology:ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4
MISTY OX® Gas Injection Nebulizer (GIN)...
... OMNI~NEB delivers breakthrough continuous low-flow ... and precise nozzle technology allows for ... with or without Heliox). OMNI~NEB takes ... in both routine and critical care ...
... Raindrop® medication nebulizer achieves optimum lung penetration ... size range is 1.04-1.10 µ at 6-8 ... air outlet., ,As the world leader ... providers the assurance of proven technology by ...
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
Medicine Products: